Frontline Treatment Considerations in Non-Small Cell Lung CancerFebruary 26th 2014
Although the current standard of care for advanced NSCLC remains platinum doublet chemotherapy, recent evidence suggests that most newly diagnosed patients may be candidates for targeted therapy as firstline treatment.
Model Emerges for Targeting Oncogenes in NSCLCDecember 3rd 2013
Between 2007 and 2011, a collaboration among clinical oncologists, pathologists, and industry scientists led to the identification of a new molecularly defined subset of NSCLC, followed by the finding that crizotinib, then under development as a MET inhibitor, was an inhibitor of ALK.
A Novel Immunotherapy Demonstrates Durable Responses in Metastatic MelanomaNovember 21st 2013
T-VEC, a novel oncolytic immunotherapy derived from the herpes simplex virus type 1, demonstrated a significant improvement in DRR, the primary endpoint in a pivotal phase III trial in patients with stage IIIB-IV melanoma.
Nivolumab Plus Ipilimumab in Advanced MelanomaNovember 20th 2013
Concurrent nivolumab and ipilimumab produced â€œrapid and deepâ€ responses in patients with advanced melanoma who took part in the first phase I trial to evaluate the PD-1-blocking antibody nivolumab, along with the CTLA-4-blocking antibody ipilimumab.
Updated Data for Pomalidomide in Relapsed/Refractory Multiple MyelomaOctober 19th 2013
In an updated analysis of the phase III MM-003 trial, Celgene International Sarl, the makers of pomalidomide, reported on a new progression-free survival (PFS) analysis and final overall survival (OS) in September 2013.
Transforming Expectations and Outcomes With Targeted TherapiesOctober 18th 2013
With the arrival and incorporation into clinical practice of immunomodulatory drugs and proteasome inhibitor therapy, patients with multiple myeloma patients are achieving deep, durable responses and disease control, and are living longer